Common use of Publications Clause in Contracts

Publications. The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method.

Publications. The Institution9.1 NNL recognises that the Thesis, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) or any of the results of the Multi-centre Study Research should be capable of being published by the University and agrees that the University Representatives engaged in the Research shall be permitted to present at symposia national or one regional professional meetings and to publish in journals or dissertations or otherwise of their own choosing the Thesis and results of the Research PROVIDING ALWAYS THAT the University shall notify NNL at least thirty (130) year after Study Completiondays prior to any submission of a publication, whichever or before any agreement is entered into to make an oral or written presentation concerning the soonerThesis or any results of the Research. The Institution must ensure that the Discloser University shall provide a draft copy of the proposed Publication publication or the presentation to NNL’s Procurement Representative. If NNL considers that the proposed publication includes a disclosure that could jeopardise measures to protect any Arising IP from the Research, then a request for delay in submission of the publication for a further eight (8) weeks, to allow Intellectual Property protection to be procured or advice sought, shall be granted by the University. If NNL considers that the proposal or publication includes a disclosure that could jeopardise its commercial interests or be a breach of national security, then either a request for a modification to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor maypublication may be made, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in without which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) Research cannot be published or the parties hereby agree that NNL can prohibit the disclosure of the publication in its entirety. 9.2 All enquiries from the Publication, press in which case connection with the Institution must remove such specified Confidential Information as is reasonably required Research shall be referred to protect the Intellectual Property NNL Procurement Representative. 9.3 Nothing in this Agreement shall preclude: 9.3.1 the disclosure of information or conclusions relating to the Research in confidence to any internal or external examiner appointed by the University in furtherance of awarding a degree to the Student subject to the University’s obligations of confidentiality in clause 7; and 9.3.2 the lodging in the academic library of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days University of giving a copy to of the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined Thesis or other material in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support regulations of the Study University with such limitations on availability and access to third parties as shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication required by another methodNNL.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide gives a draft copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting forwarding it to any person that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or or (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. Protocol Number: IHLOSAOLE1Site: ▇▇▇▇▇▇ Health 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser. 11.10 The Sponsor may only use the Institution’s and Investigators’ names: (1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement; (2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or (3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution’s prior written consent.

Publications. The Institution9.1 SPONSOR recognizes that under UNIVERSITY policy, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study UNIVERSITY Project must be publishable. UNIVERSITY agrees to submit to SPONSOR any proposed publication or one (1) year after Study Completionpresentation for prior review. SPONSOR shall, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days after receipt, advise in writing if there is any proprietary or patentable information which should not be disclosed at the present time. 9.2 Should SPONSOR desire to have information withheld from any proposed publication or presentation in order to seek protection of giving intellectual property rights, UNIVERSITY agrees not to publicly disclose such information for a copy period not to exceed six (6) months from the date of UNIVERSITY's submission to SPONSOR of any proposed publication or presentation. 9.3 UNIVERSITY acknowledges that it may be necessary for SPONSOR to disclose to UNIVERSITY information which SPONSOR considers proprietary or confidential in order to perform the Project. If SPONSOR considers any such information confidential, it shall be clearly marked "CONFIDENTIAL INFORMATION" and sent by SPONSOR in writing to the Sponsor under Clause 16.3PRINCIPAL INVESTIGATOR, or orally disclosed to the Discloser may proceed PRINCIPAL INVESTIGATOR and reduced to make writing by SPONSOR, clearly marked "CONFIDENTIAL INFORMATION" and delivered to the PublicationPRINCIPAL INVESTIGATOR within thirty (30) days of disclosure. Authorship related Except as expressly necessary for the performance of the PROJECT, UNIVERSITY shall maintain such information as confidential, not disclose it to Publications others, limit access to it to those employees with a need to know and take such action as shall be determined in accordance with reasonably necessary to ensure that its employees will not disclose it to others. 9.4 Notwithstanding the foregoing, confidential, proprietary and governed trade secret information shall not include any of the following: (a) information which is or becomes publicly available without fault by the criteria defined receiving party; (b) information which, as shown by written records, was known by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named receiving party as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy Effective Date; (c) information which, as shown by written records, is obtained by the receiving party from a third party with no obligation of confidentiality; or (d) information which, as shown by written records, was independently developed by the Publication will be furnished receiving party by employees having no access to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodinformation under this Agreement.

Publications. The InstitutionNotwithstanding Sections 11.1 to 11.5, both Parties recognize that the publication or disclosure of papers, presentations, abstracts or any other written or oral presentations regarding results of and other information regarding the Compounds or Licensed Products may be beneficial to both Parties, provided that such publications or presentations are subject to reasonable controls to protect Confidential Information, the Principal Investigator patentability of inventions and other investigators commercial considerations. Accordingly, the following shall apply with respect to papers and presentations proposed for disclosure by either Party: (a) With respect to any paper or presentation proposed for disclosure by GNE which utilizes information generated by or on behalf of GNE, so long as such paper or presentation does not contain any Confidential Information of Immunocore, GNE shall be free to make, publish Certain confidential information contained in this document, marked by [***], has been omitted because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. and disclose such papers and presentations at its discretion. GNE shall acknowledge Immunocore, as appropriate, in any publication that discloses GNE’s use of the Licensed Products or the results of any Research Program. For clarity, GNE shall not be permitted to publish or otherwise disclose any Confidential Information of Immunocore except as may be expressly permitted pursuant to Section 10.2, 10.3 or 11.6(b); and (b) With respect to any paper or presentation proposed for disclosure by (i) GNE which includes Confidential Information of Immunocore, or (ii) Immunocore which utilizes information generated by or on behalf of Immunocore relating to the Licensed Products, including without limitation any publications containing Confidential Information of GNE, (in each a case, the “DiscloserDisclosing Party”) involved in ), the Study other Party shall have the right to Publish review and approve any such proposed paper or presentation (the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws“Non-Disclosing Party”). The Sponsor, the Institution and the Principal Investigator Disclosing Party shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject submit to the other requirements Non-Disclosing Party the proposed publication or presentation (including, without limitation, posters, slides, abstracts, manuscripts, marketing materials and written descriptions of Clause 16, if oral presentations) at least [***] prior to the Study is a Multi-centre Study, then date of submission for publication or the Institution acknowledges and agrees that no Publication date of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completionpresentation, whichever is the soonerearlier, of any of such submitted materials. The Institution must ensure that Non-Disclosing Party shall review such submitted materials and respond to the Discloser provide a draft Disclosing Party as soon as reasonably possible, but in any case within [***] for abstracts) of receipt thereof. At the option of the Non-Disclosing Party, the Disclosing Party shall (a) delete from such proposed Publication publication or presentation any Confidential Information of the Non-Disclosing Party and/or (b) delay the date of such submission for publication or the date of such presentation for a period of time sufficiently long (but in no event longer than [***] to permit the Sponsor at least sixty (60) days before disclosing or transmitting it Non-Disclosing Party to any person that seek appropriate patent protection. Once a publication has been approved by the Non-Disclosing Party, the Disclosing Party may make subsequent public disclosure of the contents of such publication without the further approval of the Non-Disclosing Party; provided, such content is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do presented with any one new data or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results information or conclusions from and/or in a form or manner that materially alters the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodsubject matter therein.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide a draft gives notice of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting it any forwarding to any person a party that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Propertyproprietary rights, in which case the Institution must abide by that request; or ; (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy notice to the Sponsor under Clause 16.3clause 11.2, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication or otherwise noted as the Principal Investigator or an investigator of the Study in the Publication, will be given a reasonable opportunity to review the Publication. Publication and request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser.

Publications. The InstitutionIt is that University and Non-Profit Entity will publish the Results jointly. Nevertheless, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have Party reserves the right to Publish publish its Results separately. University shall provide Non-Profit Entity with a copy of any manuscript disclosing Results at least thirty (30) days prior to submission for publication for the methods, results of, and conclusions from, purpose of enabling Non-Profit Entity to review the Study, subject manuscript for potentially patentable Inventions with respect to this Clause 16 and which it wishes to exercise its option rights under Article 6 and/or for Confidential Information disclosed to the University Principal Investigator in accordance with all applicable intellectual property and copyright lawsArticle 7. Non-Profit Entity shall provide University with a copy of any manuscript disclosing Results at least thirty (30) days prior to submission for publication for the purpose of enabling University to review the manuscript for potentially patentable Joint Inventions with respect to which it would like to file a patent application and/or for University Confidential Information. The SponsorParty wishing to publish shall delete from its manuscript prior to submission all Confidential Information of the other Party that the other Party identifies and requests the Party wishing to publish to delete within the thirty (30) day period specified in Section 8.1. If, during the thirty (30) day period specified in Section 8.1, Non-Profit Entity notifies University that a manuscript reveals a potentially patentable Invention for which it wishes to exercise an option pursuant to Article 6, or University notifies Non-Profit Entity that a manuscript reveals a potentially patentable Joint Invention with respect to which it would like to file a patent application, the Institution Party wishing to publish shall delay publication for the purpose of enabling a patent application to be filed in accordance with Section 5.4 until the earliest to occur of: (a) a patent application has been filed with respect to such Invention; (b) University’s Office of Technology Development and Non-Profit Entity have determined that the Principal Investigator shall comply with Good Publication Practice Guidelines relevant Invention is not patentable; or (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇c) and all ethical standards concerning publications and authorshipthirty (30) days have elapsed from the date of notification under this Section 8.3. If Subject Notwithstanding anything to the other requirements contrary herein, the Parties agree to abide by the policies of Clause 16, if journals in which publications will appear as to such matters as the Study is a Multi-centre Study, then public release or availability of data or biological materials relating to the Institution acknowledges and agrees that no Publication of the Study results may publication. Proper acknowledgment will be made until Publication for the contributions of each party to the Results being published. In addition, to the extent required by applicable journal policies, each party shall use reasonable efforts to make samples of its research materials disclosed in the publication available upon request (as coordinated by the Sponsorsupplies permitting) of the results of the Multito scientists at non-centre Study or one (1) year after Study Completionprofit institutions, whichever is the sooner. The Institution must ensure provided that the Discloser provide a draft of recipient scientist agrees in writing that such research materials (a) will be used for research in the proposed Publication to the Sponsor at least sixty recipient scientist’s laboratory only, (60b) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication used for no more than one hundred and twenty any commercial purpose, (120c) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has will not received any comments from the Sponsor be used for work on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editinghuman subjects, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends (d) will not be distributed to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodother laboratories.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide gives a draft copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting forwarding it to any person that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or or (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser. 11.10 The Sponsor may only use the Institution’s and Investigators’ names: (1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement; (2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or (3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution’s prior written consent.

Publications. The InstitutionEach Party, through the Principal Investigator JSC or its designee shall provide to the other, prior to submission for publication, a draft of any articles and other investigators papers containing unpublished data relating to the Licensed Compounds or Licensed Products which have been prepared by or on behalf of such Party (each a the “DiscloserScientific Paper”) involved in the Study have the right ). With respect to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.Scientific Papers prepared by ▇▇▇▇▇., Indivior shall have forty-five (45) days after receipt thereof to notify Aelis of its observations and suggestions with respect thereto (it being understood that, during such forty- five (45) day period, no submission for publication thereof shall take place) and the Parties shall discuss these observations and suggestions. With respect to Scientific Papers prepared by ▇▇▇▇▇▇▇▇, Aelis shall have thirty (30) days after receipt thereof to notify Indivior of its observations and suggestions with respect thereto (it being understood that, during such thirty (30) day period, no submission for publication thereof shall take place) and all ethical standards concerning the Parties shall discuss these observations and suggestions. 10.3.1 With respect to publications of Scientific Papers during the License Option Period, Aelis shall reasonably incorporate the comments made by Indivior, particularly if disclosure may be prejudicial to Indivior’s opportunity to obtain, maintain, enforce or defend any Patent. Without limiting the foregoing, Indivior may require that the publication be suspended for a period of time not exceeding ninety (90) days if a Patent may be filed using Know-How covered in the proposed publication. Aelis shall provide to Indivior copies of any final Scientific Paper accepted by the journal, within ten (10) days after the approval thereof (upon availability and authorshipdistribution of such information assuming that providing such information is acceptable taking into consideration the publishers’ need to comply with any healthcare compliance guidelines). If Subject This provision will apply mutatis mutandis to the presentations, abstracts, posters or slides decks at symposia or other meetings of healthcare professionals, or congresses, conferences or meetings organized by a professional society or organization, except if these presentations abstracts, posters or slide decks incorporate data that have been approved in the context of a Scientific Paper or that have been already presented before the exercise of the License Option. 10.3.2 With respect to publications of Scientific Papers during the License Term, Aelis shall incorporate the comments made by Indivior, particularly if disclosure may be prejudicial to Indivior’s opportunity to obtain, maintain, enforce or defend any Patent, and Indivior shall incorporate reasonable comments made by ▇▇▇▇▇. Without limiting the foregoing, Indivior may also require that the publication be (a) suspended for a period of time not exceeding ninety (90) days if a Patent may be filed using Know- How covered in the proposed publication or (b) delayed indefinitely if Indivior reasonably determines that such publication would be detrimental to its patent prosecution, litigation, or other intellectual property strategy or position. 10.3.3 The party submitting the paper shall provide to the other requirements party copies of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated any final Scientific Paper accepted by the Sponsorjournal, within ten (10) days after the approval thereof (upon availability and distribution of such information assuming that providing such information is acceptable taking into consideration the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the soonerpublishers’ need to comply with any healthcare compliance guidelines). The Institution must ensure that the Discloser provide a draft of the proposed Publication This provision will apply mutatis mutandis to the Sponsor presentations, abstracts, posters or slides desks at least sixty (60) days before disclosing symposia or transmitting it to any person that is not bound other meetings of healthcare professionals, or congresses, conferences or meetings organized by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one a professional society or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodorganization.

Publications. The InstitutionFollowing the Second Restated Effective Date, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study Amicus shall have the right to Publish publish manuscripts, abstracts, or other articles in scientific journals, or to make any public presentations with respect thereto, pertaining to a Product in the methods, results of, and conclusions from, the StudyTerritory, subject to the following: 11.3.1 With respect to any presentations, publications, abstracts, or conferences regarding the subject matter of the Nov. 2013 World Congress Abstract on which Nick France (GSK) is listed as an author, Amicus shall provide to GSK such proposed manuscript (including abstracts, or presentation to a journal, editor, meeting, seminar or other third party) or proposed presentation for GSK’s review and comments at least forty-five (45) days (or fourteen (14) days for any abstract submitted to a conference or presentation to be made at a conference) prior to submission of such proposed manuscript for publication and shall reasonably consider all comments of GSK with respect thereto. GSK shall confirm receipt of such proposed manuscript. Amicus shall delete from the proposed manuscript prior to submission all Confidential Information of GSK that GSK identifies in good faith and requests to be deleted. Amicus shall not publish or present any manuscripts described in this Clause 16 and Section 11.3.1 without the prior written consent of GSK, not to be unreasonably withheld. 11.3.2 The foregoing shall not prohibit or prevent GSK from publishing any GSK-only Confidential Information, or Amicus from publishing any Amicus-only Confidential Information, in accordance with all applicable intellectual property and copyright laws. The Sponsor, each case without the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to prior written consent of the other requirements Party. 11.3.3 For the avoidance of Clause 16doubt and notwithstanding the foregoing, if GSK shall have the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of right to publish the results of any work undertaken under the MultiProgram with respect to Fabry Disease generally, any work conducted by GSK with respect to technology advancements, and any results of any non-centre Study product specific work conducted by GSK, its Affiliates, or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institutioncollaboration partners, in which case the Institution must consider such comments but will any case, that does not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified include any Amicus-only Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodInformation.

Publications. The Institution, 9.1 Company acknowledges that the Principal Investigator Investigators and other investigators (each a “Discloser”) involved in the Study University Team have the right and academic duty to Publish publish the methodsService Results, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication the University Team will be permitted to present at symposia or professional meetings and to publish in books, journals, and other media of their choosing, any and all Service Results, University Inventions, Models, and Model Improvements; provided however, that University shall not disclose Company Confidential Information without the Study results may be made until Publication (as coordinated by the Sponsor) prior written consent of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the soonerCompany. The Institution must ensure University Team will at all times have the first opportunity to publish or present the Service Results, Models, and Model Improvements subject to Section 9.2; provided however that Company shall be entitled to disclose Services Results and regulatory and/or patent filings prior to any such publication. 9.2 If University chooses to publish Service Results on its own (i.e. not publish jointly with Company), Company will be furnished a copy of any proposed publication or a summary of a presentation containing Service Results in advance of submission in the Discloser case of publication and rendering in the case of presentation. Company will have thirty (30) days after receipt to review the copy or summary for specific matter which is Company Confidential Information and provide University with a draft written request for removal or revision. If such a request is received within the thirty days, the Parties will have an additional thirty (30) days (a total of the proposed Publication to the Sponsor at least sixty (60) days before disclosing days) to agree upon removal or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required revisions to protect the Intellectual Property Company Confidential Information. Upon completion of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor this publication process or, if applicable, confidentiality is specifically waived under Clause 16.3Section 6, the Discloser University may proceed with publication, provided that University may not publish or otherwise disclose Company Confidential Information without Company’s express prior written approval. Company shall not encumber publication by University other than to make the Publication. Authorship related to Publications shall be determined remove Company Confidential Information. 9.3 All papers and presentations reporting Service Results will contain a dignified statement in accordance with a form that is customary and governed appropriate in scholarly journals or presentations for acknowledging that financial support for such research was provided by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as Company. 9.4 Company will not have an author on that Publication will be given a reasonable opportunity to review change, alter or redact the Publication. In all Publicationscontents of any student thesis, the Sponsordissertation, or presentation thereof, provided that no such thesis, dissertation or presentation may contain Company Confidential Information without Company’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodprior written consent.

Publications. The Institutionresults of the Study, as well as all the works and reports carried out and all the industrial property rights derived from this Study, are the exclusive property of the SPONSOR, who may therefore fully and freely dispose of. The SPONSOR undertakes to disseminate, once the Study is completed, the results obtained, whether negative or positive, in public access media, with mention of the research ethics committee that approved the study. The publication in scientific journals or books of the results by the main researcher of the HOSPITAL and the IDIBGI will be carried out by mutual agreement between the two parties, providing the SPONSOR with a copy of the manuscript or original so that they can know the content and make the appropriate checks with proof of receipt. The SPONSOR, within a maximum period of 30 days, will notify the main researcher of its agreement or not with its content. After the aforementioned period without any response from the SPONSOR, it will be considered that it agrees and the researcher may proceed to its publication. The Principal Investigator and other investigators / or the centers undertake not to use or transmit to third parties, nor to disclose and / or publish the results obtained in this Study without the prior written consent of the Sponsor. In any case, the following conditions must be respected: The results of the present study, assuming they are part of a multicenter study, cannot be published until the global results are published. If said multicenter publication does not occur within eighteen (each 18 months) after the end of the study, the center may then publish the results according to the following notification requirements: the center will provide a “Discloser”copy of the manuscript to the Sponsor, who will have thirty (30) involved days from receipt to review. Failure to pronounce within that period will be understood as consent. The sponsor will not cite the name of the researchers without their authorization, except in the Study have the right case of reference to Publish the methods, results of, works already published. . Any publication and conclusions from, the Study, subject to this Clause 16 and / or disclosure in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) any form of the results of medical research carried out with products of the Multi-centre Study SPONSOR provided specifically for this study, must be agreed with the SPONSOR prior to its publication and / or one (1) year after Study Completiondisclosure. In any case, whichever the legitimate interest of the SPONSOR will be protected, such as obtaining optimal patent protection, coordinating the presentation of documents to the health authorities or other studies underway in the same field, protection of confidential data. and information, etc. This section is also understood to be applicable to the soonerinformation obtained in Studies not completed or suspended before their completion. The Institution must ensure SPONSOR allows the publication of the data obtained in this Study in journals of recognized scientific prestige and its dissemination in seminars and conferences within the medical professional field, provided that the Discloser provide a draft provisions of the proposed Publication to the Sponsor at least sixty (60sections a) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12and c) of this clause are respected. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but research team will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than disclose the results of the Study) from research to third parties, with the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property exception of the Sponsorprocedure provided in this clause. If The SPONSOR will request the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy express authorizations corresponding to the Sponsor under Clause 16.3IDIBGI, the Discloser may proceed HOSPITAL and the main researcher to make the Publication. Authorship related be able to Publications shall be determined use their names in accordance with and governed by the criteria defined by the International Committee scientific publications or in any other means of Medical Journal Editors (ICMJE) “Recommendations dissemination for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results commercial or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methoddissemination purposes.

Publications. The InstitutionSubject to terms of confidentiality provided for under Clause 14 of this Agreement, the Principal Investigator Participants shall be encouraged to publish Collaboration Results of the PDP Collaboration in scientific papers, presentations, articles and any other investigators appropriate format (each a “DiscloserPublication”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇). ▇▇.▇. ▇▇▇▇.▇▇▇) and all ethical standards concerning ▇ the conclusion of the Publication Moratorium, publications and authorship. If Subject shall be referred to the other Scientific Committee for review and their recommendation shall be forwarded to the Co- Chairs who will determine its suitability before the Participant wishing to publish receives an approval to publish. The Scientific Committee and Co-Chairs shall have 30 days from receipt of a draft Publication to review and respond and propose amendments where appropriate. The Co-Chairs shall be entitled to impose an additional 90 day delay on release of a Publication where required for protection of intellectual property of Collaboration Results included in any Publication where appropriate to do so. 19.2. All Publications shall acknowledge the PDP Collaboration in a form prescribed by the Board. 19.3. Notwithstanding the Publication Moratorium OXFORD or an Associate Participant shall be entitled to publish its Academic Assay at any time during the Term in accordance with the requirements of Clause 1619.1 above, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication but where it chooses to the Sponsor at least sixty (60) days before disclosing or transmitting do so it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound eligible for the Milestone 2 payment. 19.4. Subject to follow them; request delay terms of Publication confidentiality provided under Clause 14 of this Agreement, OXFORD shall be entitled to submit data comprised in Collaboration Results, for no more than one hundred and twenty deposition in ChEMBL or similar public databases after eighteen (12018) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) months from the Publication, date of creation of such Collaboration Results save that in which case relation to Validated Academic Assays OXFORD shall not benefit from Milestone if such data submission occurs before the Institution must remove such specified Confidential Information as is reasonably required end of an applicable Publication Moratorium. 19.5. Nothing contained under this Clause 19 shall prevent the submission of an OXFORD postgraduate student’s thesis to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined examiners in accordance with and governed its normal regulations, subject where appropriate, to such examiners being bound by conditions of confidentiality in no less terms than those outlined in Clause 14, nor to the criteria defined by placing of such thesis in the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support library of the Study appropriate OXFORD department, provided that access to such thesis shall only be acknowledged. A copy available on conditions of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodconfidentiality no less onerous than those contained in Clause 14.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. law.‌ 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide gives a draft copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting forwarding it to any person that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or or (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. acknowledged.‌ 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser. 11.10 The Sponsor may only use the Institution's and Investigators’ names: (1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement; (2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or (3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution's prior written consent.

Publications. The Institution7.1 If any University personnel connected with the Research Project wish to publish (whether in writing or orally) any Confidential Information disclosed by the Sponsor to the University or any Confidential Information forming part of the Generated Intellectual Property and being, at the time it is proposed to be published, the Principal Investigator and other investigators subject of the Option or the License Agreement contemplated then subject to clause 4: (each a “Discloser”a) the University must give the Sponsor details of the information proposed to be published. The Sponsor must reply in writing within two months of receipt of proofs of the publication stating whether it approves or does not approve the publication. Where the Sponsor disapproves the publication, the Sponsor must specify in writing its reasons for that disapproval. If the Sponsor does not reply within the time specified, the Sponsor is deemed to have approved the publication. (b) The Sponsor must not withhold approval unless it reasonably believes that such GO (i) the interests which the Sponsor has in its Confidential Information (ii) the validity of any rights granted or to be granted by the License Agreement; or (iii) the potential for the registration of any Intellectual Property rights in respect of Generated Intellectual Property which is, at the time it is proposed to be published, the subject of the Option or the License Agreement. 7.2 Nothing in this Agreement prevents any student involved in the Study have Research Project from submitting any thesis or work to examiners for assessment, or the right to Publish Registrar of the methodsUniversity depositing in the library of the University a copy of the thesis or work, results ofwhich has satisfied the examiner, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property section 5 of Statute12.5 of the University Statutes; provided however that where the work or thesis contains Confidential Information as specified in clause 7. 1, the Sponsor may require the work or thesis to be submitted to the examiners in confidence and copyright lawsto then be withheld from access to library users for a maximum period of twelve months. The Where the thesis or work is altered in a material way in relation to the relevant Confidential Information after the initial date of submission to the examiner, the University must submit a copy of the amended version to the Sponsor, who must review it in accordance with the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations procedure set out in Clause 12. The subclause 7.1 above, but under no circumstances will the Sponsor may, within that sixty (60) period, do any one be entitled to require the work or more thesis to be withheld from access to library users for a period of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) twelve months from the Publication, in which case date the Institution must remove such specified Confidential Information as is reasonably required to protect work or thesis satisfied the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodexaminer.

Publications. The Institution(a) SEPRACOR will submit to BIAL drafts of all proposed publications related to SEPRACOR's development or commercialization activities in the Territory with respect to the Licensed Products no later than [**], prior to the intended submission date for publication, for review and approval by BIAL, provided however that BIAL's approval will not be unreasonably withheld or delayed. For the purposes of this Section 10.5(a), BIAL's approval will only be considered reasonably withheld in the event that (i) the publication contains Confidential Information disclosed by BIAL or on BIAL's behalf, (ii) information that creates potential statutory bars to filing a U.S., Canadian or foreign patent application, or (iii) the proposed publication will [**]. In the event of a dispute between the Parties as to whether a publication proposed by SEPRACOR will [**], the Principal Investigator dispute will be submitted to the JSC and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and will be decided in accordance with the mechanism set forth in Sections 5.5 and [**]. (b) BIAL will submit to SEPRACOR drafts of all applicable intellectual property proposed publications related to BIAL's and copyright laws. The Sponsor, its licensees development activities in the Institution and the Principal Investigator shall comply Territory with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject respect to the other requirements of Clause 16Licensed Products no later than [**], if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication prior to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person intended submission date for publication, for review and approval by SEPRACOR, provided however that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but SEPRACOR's approval will not be bound to follow them; request delay unreasonably withheld or delayed. For the purposes of Publication for no more than one hundred and twenty this Section 10.5(b), SEPRACOR's approval will only be considered reasonably withheld in the event that (120i) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified publication contains Confidential Information disclosed by SEPRACOR or on SEPRACOR's behalf, (other than the results of the Studyii) from the Publicationinformation that creates potential statutory bars to filing a U.S. or Canadian patent application, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on or (iii) the proposed Publication within sixty (60) days publication will [**]. In the event of giving a copy dispute between the Parties as to whether a publication proposed by BIAL will [**], the dispute will be submitted to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall JSC and will be determined decided in accordance with the mechanism set forth in Sections 5.5 and governed by [**]. (c) Notwithstanding anything to the criteria defined by contrary contained herein, neither Party can withhold approval of a publication of the International Committee other Party if legally obligated to make such publication. (d) For the avoidance of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publicationsdoubt, the Sponsor’s support provisions of Section 10.5(b) apply solely to publications related to BIAL's development activities in the Study shall Territory and are not applicable with respect to any of BIAL's activities, including without limitation development activities, outside the Territory. SEPRACOR acknowledges that publications relating to such BIAL activities outside the Territory may, by their own nature, be acknowledged. A copy of made available on a worldwide basis, including in the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodTerritory.

Publications. The InstitutionA. In commissioning the Research, Sponsor agrees that it is committed to publishing or otherwise disseminating publicly the Principal Investigator and other investigators (each a “Discloser”) involved in results of the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property the principles regarding authorship, conflict of interest, and copyright lawspublication ethics as expressed in the “Uniform Requirements.” All decisions regarding development, authorship, and submission of any manuscript, abstract, or other presentation arising from the Study shall be made by the Publications Committee. The Sponsor, Parties agree that the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) first publication of the results of the Multi-centre Study or one (1shall be a multicenter publication. B. The Parties agree that the author(s) year after of the initial and subsequent multicenter publication(s), as approved by the Publications Committee, shall have access to all of the data from the Study Completionand shall have the right to analyze those data, whichever is independently of Sponsor, and to prepare the soonermulticenter publication(s), independently of Sponsor, subject to Section 11 hereof. The initial multicenter publication shall be published as soon as practicable after completion of the Study, and the Publications Committee shall endeavor to submit the first multicenter publication to a reputable, peer-reviewed, biomedical journal within twelve (12) months from the end of the Study. C. The Parties agree that proposals for all publications, abstracts, and other presentations arising from the Study will be submitted for approval to the Publications Committee acting for and on behalf of all investigators and institutions participating in the Study, including Institution must ensure that and the Discloser Participating Investigator. D. In the event Institution is given authorization by the Publications Committee for an analysis or publication, Institution shall provide the Publications Committee with the manuscript, abstract, or other materials prior to any outside submission. The Publications Committee shall promptly provide a draft copy of the planned submission to the Steering Committee for review by that committee and Sponsor. Within thirty (30) business days of receipt of the proposed Publication manuscript, or within fifteen (15) business days of receipt of other presentations, the Publications Committee shall review the manuscript or other presentation, including any comments from the Steering Committee and Sponsor, and shall return to the Institution comments from the Publications Committee, the Steering Committee, and Sponsor on any aspect of the manuscript or other presentation. Institution agrees to consider said comments in good faith before any outside submission of the manuscript or other presentation. E. If Sponsor notifies the Steering Committee that Confidential Information would be released inappropriately in the manuscript or other presentation, Institution shall remove such Confidential Information from the manuscript or other presentation prior to publication or presentation, after consultation with the Publications Committee; provided, however that Sponsor will not prevent use of information that the Publications Committee finds to be necessary for the accurate presentation and interpretation of the Study results, or which is required by the publishing journal to enable other researchers to reproduce those results. F. If Sponsor notifies the Publications Committee that a manuscript or other presentation contains patentable subject matter requiring protection, then Institution shall, at least Sponsor’s written request, withhold the manuscript or other presentation from outside submission for no more than sixty (60) days before disclosing or transmitting it to any person that is not bound by from the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more date of Sponsor’s receipt of the following: provide comments on manuscript or other presentation to allow a patent application to be filed. G. Institution shall acknowledge the proposed Publication support of Sponsor in any publication or presentation arising from the Research or the Study. If a representative of Sponsor makes substantive contributions to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results intellectual content of the Studymanuscript or other presentation, as described in the “Uniform Requirements,” Institution shall invite the representative(s) from the Publication, in which case the Institution must remove such specified Confidential Information to serve as is reasonably required to protect the Intellectual Property coauthor(s) of the Sponsormanuscript or other presentation. If Acceptance of this invitation shall be at the Institution has not received any comments from discretion of the Sponsor on the proposed Publication within sixty (60) days of giving a copy representative. H. Notwithstanding anything to the contrary herein, Sponsor under Clause 16.3, the Discloser may proceed shall not have any right of or to make the Publication. Authorship related to Publications shall be determined in accordance with and governed editorial control over any publication prepared by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodpursuant hereto.

Publications. The Institution, the Principal Investigator (a) Incyte and other investigators (each a “Discloser”) involved in the Study its Affiliates shall have the right to Publish make disclosures pertaining to any Licensed Antibody or Licensed Product (other than the methods, results of, Program 1 Antibody and conclusions from, the Study, subject Program 1 Product) to this Clause 16 and Third Parties in Publications in accordance with all applicable intellectual property the following procedure: Incyte shall provide Merus with an advance copy of the proposed Publication, and copyright lawsMerus shall then have [*] prior to submission for any Publication in which to review and recommend any changes it reasonably believes are necessary to preserve any Patent Rights or Know-How belonging in [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. The SponsorConfidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested Under 17 C.F.R.§§ 200.80(b)(4) and 240-24b-2 whole or in part to Merus. If Merus informs Incyte that such Publication, in Merus’s reasonable judgment, could be expected to have a material adverse effect on any patentable invention owned by or licensed, in whole or in part, to Merus, or on any Know-How which is Confidential Information of Merus, Incyte shall delay or prevent such Publication as follows: (i) with respect to a patentable invention, such Publication shall be delayed for a sufficient period of time (not to exceed [*]) to permit the timely preparation and filing of a patent application; and (ii) with respect to Know-How which is Confidential Information of Merus, such Know-How shall be deleted from the Publication. Incyte shall have the right to present its Publications, which Publications shall be subject to the requirements in this Section 13.5, at scientific conferences, including at any conferences in any country in the world. (b) If either Party wishes to make disclosures pertaining to the Program 1 Antibody or Program 1 Product to Third Parties in Publications, the Institution and publishing Party shall provide the Principal Investigator shall comply JSC with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft an advanced copy of the proposed Publication and the JSC shall then have [*] in which to review, recommend any changes it reasonably believes are necessary to preserve any Patent Rights or Know-How belonging in whole or in party to such Party, and approve such publication. If the JSC approves the Publication or the publishing Party elects to proceed without such approval, and the non-publishing Party informs the publishing Party that such Publication, in the non-publishing Party’s reasonable judgment, could be expected to have a material adverse effect on any patentable invention owned by or licensed, in whole or in part, to the Sponsor at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information non-publishing Party (other than the results pursuant to a license granted under this Agreement), or on any Know-How which is Confidential Information of the Studynon-publishing Party, the publishing Party shall delay or prevent such Publication as follows: (i) with respect to a patentable invention, such Publication shall be delayed for a sufficient period of time (not to exceed [*]) to permit the timely preparation and filing of a patent application; and (ii) with respect to Know-How which is Confidential Information of such non-publishing Party, such Know-How shall be deleted from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method.

Publications. The InstitutionA. A "publication" shall be deemed to mean any written, oral or other public disclosure of research results, including the Principal Investigator and other investigators (each a “Discloser”) involved public use or sale of an invention based on the research results, if that event could bar the availability of protection in foreign jurisdictions or trigger the one-year grace period in the Study have the right to Publish the methods, results ofU.S. within which a U.S. patent application must be filed, and conclusions from“publish” shall have a corresponding meaning. B. UNIVERSITY shall provide each member a confidential copy of any presentation or manuscript containing results of CONSORTIUM RESEARCH that it intends to disclose or publish (whether by teaching or otherwise) at least four (4) weeks prior to the time of presentation or submission to any journal or other publication, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorshipincluding conference abstract collections. If within such period MEMBER requests redaction of any references to or data regarding MEMBER’S INVENTIONS or other MEMBER confidential information within such presentation or manuscript, UNIVERSITY shall redact such references, data and confidential information prior to presentation or submission. Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges foregoing and agrees that no Publication of the Study results may Article 3: UNIVERSITY shall be made until Publication (as coordinated by the Sponsor) of free to use the results of CONSORTIUM RESEARCH for its own teaching and educational purposes without payment of royalties or other fees provided that it does nothing which could bar the Multi-centre Study availability of patent protection in respect of a MEMBER’S INVENTION or one (1) year after Study Completion, whichever joint invention. UNIVERSITY is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication free to the Sponsor publish at least sixty (60) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than own discretion the results of CONSORTIUM RESEARCH except those that would constitute an enabling disclosure of a MEMBER’S INVENTION on which a patent application has not been filed. In such cases, the Study) UNIVERSITY may not publish without the prior written consent of the MEMBER concerned after having reviewed the full text proposed to be published. UNIVERSITY shall provide each MEMBER a confidential copy of any manuscript generated as a result of CONSORTIUM RESEARCH at the time of submission to any journal or other publication, including conference abstract collections. C. Under no circumstances will publication of a student's thesis, for which funds are derived from the PublicationCONSORTIUM, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty be delayed for longer than ninety (6090) days after conferral of giving a copy his or her degree; however, to the Sponsor under Clause 16.3extent such thesis contains references to or data regarding MEMBER’S INVENTIONS or other MEMBER confidential information, the Discloser may proceed to make the Publication. Authorship related to Publications UNIVERSITY shall be determined in accordance provide MEMBER with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A confidential copy of the Publication will be furnished such thesis and MEMBER may request to the Institution of the staff who was acknowledged upon (and UNIVERSITY shall) redact such references, data and confidential information prior to publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method.

Publications. The InstitutionNotwithstanding anything to the contrary in this Agreement, (a) prior to Alnylam’s exercise of the Principal Investigator Alnylam Commercialization Option for a particular Product pursuant to Section 4.3 and other investigators (each a “Discloser”) involved in after Alnylam declines to exercise the Study Alnylam Commercialization Option for such Product, Dicerna shall have the sole right to Publish publish the methods, results of, and conclusions from, of the StudyDevelopment activities with respect to such Product, subject to this Clause 16 the process described below; and in accordance with all applicable intellectual property and copyright laws. The Sponsor(b) after Alnylam’s exercise of the Alnylam Commercialization Option for a particular Product, the Institution Parties shall, through JCC, coordinate and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) determine publication of the results of the Multi-centre Study Development activities with respect to such Product. In the event that Dicerna desires to make any publication or one public presentation relating to a Product under clause (1a) year after Study Completionabove and such publication or presentation contains Alnylam’s Confidential Information, whichever is the sooner. The Institution must ensure that the Discloser provide Dicerna shall deliver to Alnylam a draft copy of the proposed Publication written publication or presentation at least [* * *] days prior to || submission for publication or presentation. Alnylam shall have the right (i) to propose modifications to the Sponsor publication or presentation for patent reasons, trade secret reasons or business reasons, which proposals Dicerna may accept or reject in its discretion (except that Dicerna shall be required to remove any Confidential Information of Alnylam at least sixty Alnylam’s request), and (60ii) days before disclosing to request a reasonable delay in publication or transmitting it presentation in order to any person that is not bound by the confidentiality obligations set out protect patentable information in Clause 12accordance with Article 8. The Sponsor mayIf Alnylam requests a delay pursuant to clause (ii), within that sixty (60) period, do any one Dicerna shall delay submission or more of the following: provide comments on the proposed Publication presentation for up to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) a [* * *] additional days to allow the Sponsor enable Alnylam to file patent applications or take other measures to preserve or secure its Intellectual Property, protecting Alnylam’s rights in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined information in accordance with and governed Article 8. In any scientific publication in the scientific literature (journal article, book chapter, poster) referencing data created or generated by Alnylam related to the criteria defined by Products, Dicerna shall endeavor to include appropriate acknowledgements, consistent with the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where Journals published by the Sponsor intends to Publish the methodInternational Committee of Medical Journal Editors, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy related roles and contributions of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results Alnylam and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodsuch entities’ respective individual involved scientists.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide gives a draft copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting forwarding it to any person that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or or (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser. 11.10 The Sponsor may only use the Institution's and Investigators’ names: (1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement; (2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or (3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution's prior written consent.

Publications. The InstitutionA. Notwithstanding anything contained herein to the contrary, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the and/or Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of publish the results of the MultiStudy in scientific publications, provided that the Investigator and/or Institution have notified the Sponsor of their intent to publish and have received the consent of the Sponsor as set forth in Sub-centre Study or one (1) year after Study Completion, whichever is the soonerSection B below. The Investigator and/or Institution must ensure that and the Discloser Sponsor shall be listed as co-authors on said publication. Any said scientific publication will not contain the Sponsor’s Confidential Information without the Sponsor’s prior written approval, which for the purpose of this section shall not include the Study results. B. The Investigator will provide Sponsor with a draft copy of any proposed publication or presentation materials (“Material”) and a written notice of intent (on behalf of the proposed Publication Investigator or any Study staff at the Institution) to publish or present the Material at least 45 days prior to the scheduled presentation or publication submission date (the “Evaluation Period”), during which Sponsor at least shall inform the Investigator and the Institution if (i) it wishes to seek patent protection for any such Material, and (ii) if any such material contains New IP that is not patentable that is supported by an Israeli patent attorney opinion (“New Trade Secrets”). If the Sponsor does not so notify the Investigator within the Evaluation Period, the Sponsor shall be deemed to have given its consent to publication of the Material. If the Sponsor so notifies the Investigator within the Evaluation Period, (i) the material shall be edited to remove the New Trade Secrets, if any, and (ii) the Sponsor shall have an additional sixty (60) days before disclosing days, beginning from the end of the Evaluation Period to prepare and submit any patent application it wishes or transmitting it to any person achieve an Israeli patent attorney opinion that New IP is not bound by patentable, and after such time, Investigator and/or Institution shall be free to publish the confidentiality obligations set out in Clause 12. The Material, other than New Trade Secrets subject to the limitations contained herein. C. Notwithstanding anything to the contrary herein, the Sponsor may, within that sixty (60) period, do any one or more shall not use the names of the following: provide comments on Institution, HMO or the proposed Publication Investigator and shall not disclose their involvement in the Study or the Products without the Institution’s prior written approval, all except for (a) references to publications which are already in the public domain at the time of publication and (b) applications for regulatory approvals to official authorities, and (c) as requested by regulatory authorities or as required by law or applicable regulation or stock exchange rule and/or regulation. Subject to the foregoing, the Sponsor shall include appropriate acknowledgement and credit to the Institution, HMO, the Investigator and their employees in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy publication relating to the Sponsor under Clause 16.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished and/or to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before Product in whatever media, including application(s) to official authorities or after Publication by another methodpresentations to potential investors.

Publications. The InstitutionProject will form part of the actual carrying out of a primary charitable purpose of the University; that is, the Principal Investigator advancement of education through teaching and other investigators research. In accordance with normal academic practice, all employees, students, agents or appointees of the University (each a “Discloser”including the Student and any others who work on the Project) involved shall be permitted, following the procedures laid down in the Study have the right Clause 6.3, to Publish the methods, results ofpublish Arising Intellectual Property or discuss Arising Intellectual Property in internal seminars, and conclusions fromto give instructions within the University on questions related to such work. All proposed publications (including, the Studybut not limited to, subject to this Clause 16 academic publications, patent applications and non-confidential presentations), shall be submitted in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject writing to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by Partner Organisation and the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. The Institution must ensure that the Discloser provide a draft of the proposed Publication to the Sponsor University for review at least sixty thirty (6030) days before disclosing submission for publication or transmitting it to any person that is not bound by before presentation, as the confidentiality obligations set out in Clause 12case may be. The Sponsor may, within that sixty (60) period, do any one or more of reviewing Party may require the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than the results of the Study) deletion from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the publication of any Background Intellectual Property of the Sponsorreviewing Party, or an amendment to the publication through which commercially sensitive Background Intellectual Property is disguised to the satisfaction of the reviewing Party. If The reviewing Party may also request the Institution has delay of the publication if in the reviewing Party’s opinion the delay is necessary in order to seek patent or similar protection to Arising Intellectual Property owned by the reviewing Party. Any delay imposed on publication shall not received any comments last longer than is reasonably necessary for the reviewing Party to obtain the required protection; and shall not exceed six (6) months from the Sponsor on date of receipt of the proposed Publication publication by the reviewing Party. Notification of the requirement for delay in publication must be received by the publishing Party within sixty thirty (6030) days after receipt of giving a copy the proposed publication by the reviewing Party, failing which the publishing Party shall be free to assume that the reviewing Party has no objection to the Sponsor under Clause 16.3, proposed publication. Each Party agrees that any publication in an academic journal shall give due acknowledgement to the Discloser may proceed to make financial and/or intellectual contribution of the Publication. Authorship related to Publications shall be determined others in accordance with and standard scientific practice. Clause 6 does not apply to the submission of the Thesis, which is governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methodClause 7.

Publications. ‌ 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide a draft gives notice of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting it any forwarding to any person a party that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Propertyproprietary rights, in which case the Institution must abide by that request; or ; (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. Sponsor.‌ 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy notice to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication or otherwise noted as the Principal Investigator or an investigator of the Study in the Publication, will be given a reasonable opportunity to review the Publication. Publication and request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser.

Publications. 8.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year after Study Completion, whichever is the sooner. 8.2 The Institution must ensure that the Discloser provide a draft gives notice of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor Company at least sixty (60) 40 days before disclosing or transmitting it any forwarding to any person a party that is not bound by the confidentiality obligations set out in Clause 12. The Sponsor clause 5. 8.3 Company may, within that sixty (60) period, 40-day period do any one or more of the following: : 8.3.1 provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; 8.3.2 request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor Company to file patent applications or take other measures to preserve or secure its Intellectual Propertyproprietary rights, in which case the Institution must abide by that request; or ; 8.3.3 request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 8.4 If the Institution has not received any comments from the Sponsor Company on the proposed Publication within sixty (60) 40 days of giving a copy notice to the Sponsor Company under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 8.5 Where the Sponsor Company intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication or otherwise noted as the Principal Investigator or an investigator of the Study in the Publication, will be given a reasonable opportunity to review the Publication. Publication and request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 8.6 In all Publications, the SponsorPublications Company’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor . 8.7 Company may Publish a summary of the study results Study Results and conclusions on the Sponsor’s Company's on-line Clinical Trial Register before or after Publication by another method. 8.8 Company may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser.

Publications. The Institutionresults of the Study, as well as all the works and reports carried out and all the industrial property rights derived from this Study, are the exclusive property of the PROMOTER, who may therefore fully and freely dispose of. The SPONSOR undertakes to disseminate, once the Study is completed, the results obtained, whether negative or positive, in public access media, with mention of the research ethics committee that approved the study. The publication in scientific journals or books of the results by the main researcher of the HOSPITAL and the IDIBGI will be carried out by mutual agreement between the two parties, providing the PROMOTER with a copy of the manuscript or original so that they can know the content and make the appropriate checks with proof of receipt. The SPONSOR, within a maximum period of 30 days, will notify the main researcher of its agreement or not with its content. After the aforementioned period without any response from the SPONSOR, it will be considered that it agrees and the researcher may proceed to its publication. The Principal Investigator and other investigators / or the centers undertake not to use or transmit to third parties, nor to disclose and / or publish the results obtained in this Study without the prior written consent of the Sponsor. In any case, the following conditions must be respected: The results of the present study, assuming they are part of a multicenter study, cannot be published until the global results are published. If said multicenter publication does not occur within eighteen (each 18 months) after the end of the study, the center may then publish the results according to the following notification requirements: the center will provide a “Discloser”copy of the manuscript to the Sponsor, who will have thirty (30) involved days from receipt to review. Failure to pronounce within that period will be understood as consent. The sponsor will not cite the name of the researchers without their authorization, except in the Study have the right case of reference to Publish the methods, results of, works already published. . Any publication and conclusions from, the Study, subject to this Clause 16 and / or disclosure in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) any form of the results of medical research carried out with products of the Multi-centre Study promoter provided specifically for this study, must be agreed with the promoter prior to its publication and / or one (1) year after Study Completiondisclosure. In any case, whichever the legitimate interest of the promoter will be protected, such as obtaining optimal patent protection, coordinating the presentation of documents to the health authorities or other studies underway in the same field, protection of confidential data. and information, etc. This section is also understood to be applicable to the soonerinformation obtained in Studies not completed or suspended before their completion. The Institution must ensure promoter allows the publication of the data obtained in this Study in journals of recognized scientific prestige and its dissemination in seminars and conferences within the medical professional field, provided that the Discloser provide a draft provisions of the proposed Publication to the Sponsor at least sixty (60sections a) days before disclosing or transmitting it to any person that is not bound by the confidentiality obligations set out in Clause 12and c) of this clause are respected. The Sponsor may, within that sixty (60) period, do any one or more of the following: provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but research team will not be bound to follow them; request delay of Publication for no more than one hundred and twenty (120) days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or request that the Discloser remove specified Confidential Information (other than disclose the results of the Study) from research to third parties, with the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property exception of the Sponsorprocedure provided in this clause. If The SPONSOR will request the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) days of giving a copy express authorizations corresponding to the Sponsor under Clause 16.3IDIBGI, the Discloser may proceed HOSPITAL and the main researcher to make the Publication. Authorship related be able to Publications shall be determined use their names in accordance with and governed by the criteria defined by the International Committee scientific publications or in any other means of Medical Journal Editors (ICMJE) “Recommendations dissemination for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” Where the Sponsor intends to Publish the method, results commercial or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. In all Publications, the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. The Sponsor may Publish a summary of the study results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another methoddissemination purposes.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication. 11.3 The Institution must ensure that the Discloser provide a draft gives notice of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting it any forwarding to any person a party that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; ; (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Propertyproprietary rights, in which case the Institution must abide by that request; or ; (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy notice to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication or otherwise noted as the Principal Investigator or an investigator of the Study in the Publication, will be given a reasonable opportunity to review the Publication. Publication and request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. . 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser.

Publications. 11.1 The Institution, the Principal Investigator and other investigators (each a “Discloser”) involved in the Study have the right to Publish the methods, results of, and conclusions from, the Study, subject to this Clause 16 clause and in accordance with all applicable intellectual property and copyright laws. The Sponsor, the Institution and the Principal Investigator shall comply with Good Publication Practice Guidelines (▇▇▇▇://▇▇▇law.▇▇▇▇▇.▇▇▇) and all ethical standards concerning publications and authorship. 11.2 If Subject to the other requirements of Clause 16, if the Study is a Multi-centre Study, then the Institution acknowledges and agrees that no Publication of the Study results may be made until Publication (as coordinated by the Sponsor) of the results of the Multi-centre Study or one (1) year 2 years after Study Completion, whichever is the sooner. The further provisions of this clause still apply to any such Publication.‌ 11.3 The Institution must ensure that the Discloser provide gives a draft copy of any proposed Publication drafted by them and/or other Personnel involved in the conduct of the proposed Publication Study to the Sponsor at least sixty (60) 40 days before disclosing or transmitting forwarding it to any person that is not bound by the confidentiality obligations set out in Clause 12. clause 9. 11.4 The Sponsor may, within that sixty (60) period, 40-day period do any one or more of the following: : (1) provide comments on the proposed Publication to the Institution, in which case the Institution must consider such comments but will not be bound to follow them; them;‌ (2) request delay of Publication for no more than one hundred and twenty (120) 120 days to allow the Sponsor to file patent applications or take other measures to preserve or secure its Intellectual Property, in which case the Institution must abide by that request; or or (3) request that the Discloser remove specified Confidential Information (other than the results of the Study) from the Publication, in which case the Institution must remove such specified Confidential Information as is reasonably required to protect the Intellectual Property of the Sponsor. . 11.5 If the Institution has not received any comments from the Sponsor on the proposed Publication within sixty (60) 40 days of giving a copy to the Sponsor under Clause 16.3clause 11.3, the Discloser may proceed to make the Publication. Authorship related to Publications shall be determined in accordance with and governed by the criteria defined by the International Committee of Medical Journal Editors (ICMJE) “Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals” . 11.6 Where the Sponsor intends to Publish the method, results or conclusions from the Study, any person named as an author on that Publication will be given a reasonable opportunity to review the Publication. Any person acknowledged as an investigator of the Study in the Publication will be given a reasonable opportunity to request the removal of his or her name from the Publication and the Sponsor shall comply with any such request. 11.7 In all Publications, Publications the Sponsor’s support of the Study shall be acknowledged. A copy of the Publication will be furnished to the Institution of the staff who was acknowledged upon publication. acknowledged.‌ 11.8 The Sponsor may Publish a summary of the study results Study Results and conclusions on the Sponsor’s on-line Clinical Trial Register before or after Publication by another method. 11.9 The Sponsor may freely use, copy and disseminate any manuscript following its Publication in a journal without further obligation to the Institution or Discloser. 11.10 The Sponsor may only use the Institution's and Investigators’ names:‌ (1) in relation to the publication of the Study on reputable clinical trials registers and websites in accordance with the CONSORT 2010 Statement; (2) in Study publications and communications including Study newsletters made to the Institution and any other person which is subject to substantially the same confidentiality obligations as those set out in clause 9, in relation to performance of the Study; or‌ (3) in Study publications and communications made to any third party not subject to the confidentiality obligations set out in clause 9, with the Institution's prior written consent.